CA2649457A1 - Vaccins a base d'une nanoemulsion - Google Patents

Vaccins a base d'une nanoemulsion Download PDF

Info

Publication number: CA2649457A1
Authority: CA; Canada
Prior art keywords: composition; vol; subject; immunity; nanoemulsion
Prior art date: 2006-04-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002649457A

Other languages

English (en)

Inventor

James R. Baker, Jr.

Anna Bielinska

Andrzej Myc

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Michigan

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-13

Filing date

2007-04-13

Publication date

2007-10-25

2007-04-13 Application filed by Individual filed Critical Individual

2007-04-13 Priority to CA2912900A priority Critical patent/CA2912900A1/fr

2007-10-25 Publication of CA2649457A1 publication Critical patent/CA2649457A1/fr

Status Abandoned legal-status Critical Current

Links

239000007908 nanoemulsion Substances 0.000 title claims abstract description 380
229960005486 vaccine Drugs 0.000 title abstract description 90
239000000203 mixture Substances 0.000 claims abstract description 541
230000036039 immunity Effects 0.000 claims abstract description 143
238000000034 method Methods 0.000 claims abstract description 122
239000002671 adjuvant Substances 0.000 claims abstract description 52
230000028993 immune response Effects 0.000 claims description 176
230000002163 immunogen Effects 0.000 claims description 120
241000700629 Orthopoxvirus Species 0.000 claims description 77
241000193738 Bacillus anthracis Species 0.000 claims description 75
241000700618 Vaccinia virus Species 0.000 claims description 65
230000004044 response Effects 0.000 claims description 51
241000700605 Viruses Species 0.000 claims description 48
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
201000010099 disease Diseases 0.000 claims description 45
230000009885 systemic effect Effects 0.000 claims description 40
230000001939 inductive effect Effects 0.000 claims description 38
230000004936 stimulating effect Effects 0.000 claims description 30
208000024891 symptom Diseases 0.000 claims description 24
101710194807 Protective antigen Proteins 0.000 claims description 23
230000001965 increasing effect Effects 0.000 claims description 18
241000700647 Variola virus Species 0.000 claims description 15
230000014509 gene expression Effects 0.000 claims description 11
201000003740 cowpox Diseases 0.000 claims description 8
208000005871 monkeypox Diseases 0.000 claims description 8
210000002850 nasal mucosa Anatomy 0.000 claims description 7
208000030507 AIDS Diseases 0.000 claims description 6
108091034117 Oligonucleotide Proteins 0.000 claims description 6
229940035032 monophosphoryl lipid a Drugs 0.000 claims description 3
LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 claims 2
244000052769 pathogen Species 0.000 abstract description 84
150000001875 compounds Chemical class 0.000 abstract description 72
230000001717 pathogenic effect Effects 0.000 abstract description 59
102000004169 proteins and genes Human genes 0.000 abstract description 45
108090000623 proteins and genes Proteins 0.000 abstract description 45
230000027317 positive regulation of immune response Effects 0.000 abstract description 5
230000007613 environmental effect Effects 0.000 abstract description 4
230000001976 improved effect Effects 0.000 abstract description 3
244000000015 environmental pathogen Species 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 282
239000003549 soybean oil Substances 0.000 description 199
235000012424 soybean oil Nutrition 0.000 description 199
229960001927 cetylpyridinium chloride Drugs 0.000 description 174
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 174
239000000839 emulsion Substances 0.000 description 145
-1 but not limited to Substances 0.000 description 130
238000009472 formulation Methods 0.000 description 123
239000003921 oil Substances 0.000 description 115
235000019198 oils Nutrition 0.000 description 115
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 114
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 105
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 85
STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 84
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 63
239000002953 phosphate buffered saline Substances 0.000 description 63
239000008346 aqueous phase Substances 0.000 description 60
239000012071 phase Substances 0.000 description 60
241000725303 Human immunodeficiency virus Species 0.000 description 56
229920001664 tyloxapol Polymers 0.000 description 52
MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 52
229960004224 tyloxapol Drugs 0.000 description 52
239000003795 chemical substances by application Substances 0.000 description 51
241000894006 Bacteria Species 0.000 description 49
241000699670 Mus sp. Species 0.000 description 46
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
235000018102 proteins Nutrition 0.000 description 44
235000019270 ammonium chloride Nutrition 0.000 description 43
241001465754 Metazoa Species 0.000 description 42
229920001213 Polysorbate 20 Polymers 0.000 description 41
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 41
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 41
239000004094 surface-active agent Substances 0.000 description 40
235000011187 glycerol Nutrition 0.000 description 38
108091007433 antigens Proteins 0.000 description 32
102000036639 antigens Human genes 0.000 description 32
210000004027 cell Anatomy 0.000 description 31
230000007246 mechanism Effects 0.000 description 31
238000002255 vaccination Methods 0.000 description 31
239000000427 antigen Substances 0.000 description 30
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 29
229960003767 alanine Drugs 0.000 description 29
230000004224 protection Effects 0.000 description 29
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 28
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 28
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 28
244000005700 microbiome Species 0.000 description 28
210000000987 immune system Anatomy 0.000 description 27
229920001214 Polysorbate 60 Polymers 0.000 description 26
239000003623 enhancer Substances 0.000 description 26
244000068988 Glycine max Species 0.000 description 25
239000004006 olive oil Substances 0.000 description 24
235000008390 olive oil Nutrition 0.000 description 24
229930010555 Inosine Natural products 0.000 description 23
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 23
230000035784 germination Effects 0.000 description 23
208000015181 infectious disease Diseases 0.000 description 23
229960003786 inosine Drugs 0.000 description 23
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 22
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 22
239000000463 material Substances 0.000 description 22
230000003993 interaction Effects 0.000 description 21
210000002966 serum Anatomy 0.000 description 21
241000193830 Bacillus <bacterium> Species 0.000 description 20
229910052736 halogen Inorganic materials 0.000 description 20
229920000136 polysorbate Polymers 0.000 description 20
230000000694 effects Effects 0.000 description 19
230000010534 mechanism of action Effects 0.000 description 19
230000003472 neutralizing effect Effects 0.000 description 19
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 18
230000006698 induction Effects 0.000 description 18
125000000217 alkyl group Chemical group 0.000 description 17
239000003599 detergent Substances 0.000 description 17
230000002779 inactivation Effects 0.000 description 17
230000001681 protective effect Effects 0.000 description 17
239000002904 solvent Substances 0.000 description 17
RUPBZQFQVRMKDG-UHFFFAOYSA-M Didecyldimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC RUPBZQFQVRMKDG-UHFFFAOYSA-M 0.000 description 16
241000282412 Homo Species 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
238000011161 development Methods 0.000 description 15
230000018109 developmental process Effects 0.000 description 15
150000003839 salts Chemical class 0.000 description 15
239000000243 solution Substances 0.000 description 15
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 14
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 14
210000004443 dendritic cell Anatomy 0.000 description 14
231100000252 nontoxic Toxicity 0.000 description 14
230000003000 nontoxic effect Effects 0.000 description 14
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 13
241000700198 Cavia Species 0.000 description 13
239000002480 mineral oil Substances 0.000 description 13
235000010446 mineral oil Nutrition 0.000 description 13
108090000765 processed proteins & peptides Proteins 0.000 description 13
210000004215 spore Anatomy 0.000 description 13
210000001519 tissue Anatomy 0.000 description 13
230000001413 cellular effect Effects 0.000 description 12
IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 12
230000003053 immunization Effects 0.000 description 12
238000002649 immunization Methods 0.000 description 12
210000001744 T-lymphocyte Anatomy 0.000 description 11
206010046865 Vaccinia virus infection Diseases 0.000 description 11
238000010171 animal model Methods 0.000 description 11
210000003719 b-lymphocyte Anatomy 0.000 description 11
208000007089 vaccinia Diseases 0.000 description 11
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 10
BOBBYBHJYYJHHQ-UHFFFAOYSA-N 7-tert-butyl-6-(4-chlorophenyl)-2-sulfanylidene-1h-pyrido[2,3-d]pyrimidin-4-one Chemical compound CC(C)(C)C1=NC=2NC(=S)NC(=O)C=2C=C1C1=CC=C(Cl)C=C1 BOBBYBHJYYJHHQ-UHFFFAOYSA-N 0.000 description 10
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
229910019142 PO4 Inorganic materials 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
229930182558 Sterol Natural products 0.000 description 10
230000004913 activation Effects 0.000 description 10
230000000845 anti-microbial effect Effects 0.000 description 10
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 10
235000013350 formula milk Nutrition 0.000 description 10
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 10
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 10
239000010452 phosphate Substances 0.000 description 10
235000003702 sterols Nutrition 0.000 description 10
235000010469 Glycine max Nutrition 0.000 description 9
239000002211 L-ascorbic acid Substances 0.000 description 9
235000000069 L-ascorbic acid Nutrition 0.000 description 9
229960005070 ascorbic acid Drugs 0.000 description 9
230000001580 bacterial effect Effects 0.000 description 9
229910052799 carbon Inorganic materials 0.000 description 9
238000011260 co-administration Methods 0.000 description 9
230000028996 humoral immune response Effects 0.000 description 9
150000002632 lipids Chemical group 0.000 description 9
210000004877 mucosa Anatomy 0.000 description 9
238000006386 neutralization reaction Methods 0.000 description 9
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 9
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
230000035755 proliferation Effects 0.000 description 9
230000003248 secreting effect Effects 0.000 description 9
210000004988 splenocyte Anatomy 0.000 description 9
150000003432 sterols Chemical class 0.000 description 9
239000000126 substance Substances 0.000 description 9
239000003053 toxin Substances 0.000 description 9
231100000765 toxin Toxicity 0.000 description 9
108700012359 toxins Proteins 0.000 description 9
102000004127 Cytokines Human genes 0.000 description 8
108090000695 Cytokines Proteins 0.000 description 8
108020004414 DNA Proteins 0.000 description 8
241000233866 Fungi Species 0.000 description 8
239000013504 Triton X-100 Substances 0.000 description 8
229920004890 Triton X-100 Polymers 0.000 description 8
235000014121 butter Nutrition 0.000 description 8
229960004670 didecyldimethylammonium chloride Drugs 0.000 description 8
239000000422 germination enhancer Substances 0.000 description 8
230000002757 inflammatory effect Effects 0.000 description 8
230000001404 mediated effect Effects 0.000 description 8
210000004379 membrane Anatomy 0.000 description 8
239000012528 membrane Substances 0.000 description 8
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
210000004400 mucous membrane Anatomy 0.000 description 8
229940113124 polysorbate 60 Drugs 0.000 description 8
210000003491 skin Anatomy 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 8
235000019345 sodium thiosulphate Nutrition 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
239000001974 tryptic soy broth Substances 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
241000196324 Embryophyta Species 0.000 description 7
239000002253 acid Substances 0.000 description 7
230000003044 adaptive effect Effects 0.000 description 7
229940024606 amino acid Drugs 0.000 description 7
230000005875 antibody response Effects 0.000 description 7
210000000612 antigen-presenting cell Anatomy 0.000 description 7
230000000890 antigenic effect Effects 0.000 description 7
230000000415 inactivating effect Effects 0.000 description 7
210000002540 macrophage Anatomy 0.000 description 7
239000007764 o/w emulsion Substances 0.000 description 7
230000036961 partial effect Effects 0.000 description 7
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
229920000053 polysorbate 80 Polymers 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
238000011160 research Methods 0.000 description 7
239000001509 sodium citrate Substances 0.000 description 7
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 7
230000003330 sporicidal effect Effects 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
QAQSNXHKHKONNS-UHFFFAOYSA-N 1-ethyl-2-hydroxy-4-methyl-6-oxopyridine-3-carboxamide Chemical compound CCN1C(O)=C(C(N)=O)C(C)=CC1=O QAQSNXHKHKONNS-UHFFFAOYSA-N 0.000 description 6
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
230000024932 T cell mediated immunity Effects 0.000 description 6
ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 6
XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
230000003115 biocidal effect Effects 0.000 description 6
239000000872 buffer Substances 0.000 description 6
235000005687 corn oil Nutrition 0.000 description 6
239000002285 corn oil Substances 0.000 description 6
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
229960000878 docusate sodium Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000003937 drug carrier Substances 0.000 description 6
230000006870 function Effects 0.000 description 6
230000002209 hydrophobic effect Effects 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
210000004072 lung Anatomy 0.000 description 6
239000003960 organic solvent Substances 0.000 description 6
150000003856 quaternary ammonium compounds Chemical class 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 6
235000019333 sodium laurylsulphate Nutrition 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
230000001988 toxicity Effects 0.000 description 6
231100000419 toxicity Toxicity 0.000 description 6
108010050327 trypticase-soy broth Proteins 0.000 description 6
241000712461 unidentified influenza virus Species 0.000 description 6
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
229920000604 Polyethylene Glycol 200 Polymers 0.000 description 5
241000700159 Rattus Species 0.000 description 5
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
230000030741 antigen processing and presentation Effects 0.000 description 5
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 5
244000052616 bacterial pathogen Species 0.000 description 5
210000004666 bacterial spore Anatomy 0.000 description 5
239000002585 base Substances 0.000 description 5
229960000686 benzalkonium chloride Drugs 0.000 description 5
OCBHHZMJRVXXQK-UHFFFAOYSA-M benzyl-dimethyl-tetradecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 OCBHHZMJRVXXQK-UHFFFAOYSA-M 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
229940041514 candida albicans extract Drugs 0.000 description 5
230000007969 cellular immunity Effects 0.000 description 5
239000002738 chelating agent Substances 0.000 description 5
239000003240 coconut oil Substances 0.000 description 5
235000019864 coconut oil Nutrition 0.000 description 5
235000012343 cottonseed oil Nutrition 0.000 description 5
239000002385 cottonseed oil Substances 0.000 description 5
239000008121 dextrose Substances 0.000 description 5
239000012636 effector Substances 0.000 description 5
239000003995 emulsifying agent Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000000499 gel Substances 0.000 description 5
230000012010 growth Effects 0.000 description 5
150000002367 halogens Chemical class 0.000 description 5
229960001438 immunostimulant agent Drugs 0.000 description 5
230000000977 initiatory effect Effects 0.000 description 5
239000002085 irritant Substances 0.000 description 5
231100000021 irritant Toxicity 0.000 description 5
230000002147 killing effect Effects 0.000 description 5
239000000787 lecithin Substances 0.000 description 5
235000010445 lecithin Nutrition 0.000 description 5
229940067606 lecithin Drugs 0.000 description 5
231100000518 lethal Toxicity 0.000 description 5
230000001665 lethal effect Effects 0.000 description 5
239000000944 linseed oil Substances 0.000 description 5
235000021388 linseed oil Nutrition 0.000 description 5
239000007788 liquid Substances 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
239000011148 porous material Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
230000009257 reactivity Effects 0.000 description 5
241000894007 species Species 0.000 description 5
230000000087 stabilizing effect Effects 0.000 description 5
230000032258 transport Effects 0.000 description 5
239000012138 yeast extract Substances 0.000 description 5
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
HUHGPYXAVBJSJV-UHFFFAOYSA-N 2-[3,5-bis(2-hydroxyethyl)-1,3,5-triazinan-1-yl]ethanol Chemical compound OCCN1CN(CCO)CN(CCO)C1 HUHGPYXAVBJSJV-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 4
229920003091 Methocel™ Polymers 0.000 description 4
241000607626 Vibrio cholerae Species 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
229940065181 bacillus anthracis Drugs 0.000 description 4
239000001110 calcium chloride Substances 0.000 description 4
229910001628 calcium chloride Inorganic materials 0.000 description 4
125000002091 cationic group Chemical group 0.000 description 4
SXPWTBGAZSPLHA-UHFFFAOYSA-M cetalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SXPWTBGAZSPLHA-UHFFFAOYSA-M 0.000 description 4
230000034994 death Effects 0.000 description 4
231100000517 death Toxicity 0.000 description 4
230000007123 defense Effects 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
230000002708 enhancing effect Effects 0.000 description 4
210000002919 epithelial cell Anatomy 0.000 description 4
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
239000012530 fluid Substances 0.000 description 4
230000036541 health Effects 0.000 description 4
230000004727 humoral immunity Effects 0.000 description 4
230000008348 humoral response Effects 0.000 description 4
230000001524 infective effect Effects 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
230000000968 intestinal effect Effects 0.000 description 4
239000001525 mentha piperita l. herb oil Substances 0.000 description 4
YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 4
229960002216 methylparaben Drugs 0.000 description 4
230000000813 microbial effect Effects 0.000 description 4
244000000010 microbial pathogen Species 0.000 description 4
238000002156 mixing Methods 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
229960005030 other vaccine in atc Drugs 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
235000019477 peppermint oil Nutrition 0.000 description 4
229920002523 polyethylene Glycol 1000 Polymers 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
229950008882 polysorbate Drugs 0.000 description 4
229940083538 smallpox vaccine Drugs 0.000 description 4
239000011734 sodium Substances 0.000 description 4
239000007921 spray Substances 0.000 description 4
238000003860 storage Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
244000052613 viral pathogen Species 0.000 description 4
YGKOYVNJPRSSRX-UHFFFAOYSA-M (4-dodecylphenyl)methyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC1=CC=C(C[N+](C)(C)C)C=C1 YGKOYVNJPRSSRX-UHFFFAOYSA-M 0.000 description 3
JUSZROWIGBIXOS-UHFFFAOYSA-N 1-(dimethylamino)propan-2-ol;hydrochloride Chemical compound [Cl-].CC(O)C[NH+](C)C JUSZROWIGBIXOS-UHFFFAOYSA-N 0.000 description 3
SWWQQSDRUYSMAR-UHFFFAOYSA-N 1-[(4-hydroxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrochloride Chemical group Cl.C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 SWWQQSDRUYSMAR-UHFFFAOYSA-N 0.000 description 3
PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
JMHWNJGXUIJPKG-UHFFFAOYSA-N CC(=O)O[SiH](CC=C)OC(C)=O Chemical compound CC(=O)O[SiH](CC=C)OC(C)=O JMHWNJGXUIJPKG-UHFFFAOYSA-N 0.000 description 3
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
208000035473 Communicable disease Diseases 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
208000031886 HIV Infections Diseases 0.000 description 3
241000709721 Hepatovirus A Species 0.000 description 3
241000204031 Mycoplasma Species 0.000 description 3
CBSOFSBFHDQRLV-UHFFFAOYSA-N N-methylbenzylamine hydrochloride Chemical compound [Cl-].C[NH2+]CC1=CC=CC=C1 CBSOFSBFHDQRLV-UHFFFAOYSA-N 0.000 description 3
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
206010037660 Pyrexia Diseases 0.000 description 3
206010037888 Rash pustular Diseases 0.000 description 3
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 3
206010041660 Splenomegaly Diseases 0.000 description 3
108010003533 Viral Envelope Proteins Proteins 0.000 description 3
108010067390 Viral Proteins Proteins 0.000 description 3
230000002411 adverse Effects 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
125000000129 anionic group Chemical group 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
239000004599 antimicrobial Substances 0.000 description 3
239000002199 base oil Substances 0.000 description 3
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 3
230000024245 cell differentiation Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000000356 contaminant Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
SCXCDVTWABNWLW-UHFFFAOYSA-M decyl-dimethyl-octylazanium;chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCC SCXCDVTWABNWLW-UHFFFAOYSA-M 0.000 description 3
NLFTWRWHIFBVRC-UHFFFAOYSA-M dodecyl-dimethyl-octylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CCCCCCCC NLFTWRWHIFBVRC-UHFFFAOYSA-M 0.000 description 3
230000001804 emulsifying effect Effects 0.000 description 3
206010017931 gastrointestinal anthrax Diseases 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
150000002431 hydrogen Chemical class 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
206010020718 hyperplasia Diseases 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000021633 leukocyte mediated immunity Effects 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
230000001320 lysogenic effect Effects 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
230000016379 mucosal immune response Effects 0.000 description 3
229940094510 myristalkonium chloride Drugs 0.000 description 3
239000002736 nonionic surfactant Substances 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000002962 plaque-reduction assay Methods 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
208000029561 pustule Diseases 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
230000000717 retained effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
229940038774 squalene oil Drugs 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
238000011282 treatment Methods 0.000 description 3
PZJJKWKADRNWSW-UHFFFAOYSA-N trimethoxysilicon Chemical group CO[Si](OC)OC PZJJKWKADRNWSW-UHFFFAOYSA-N 0.000 description 3
210000001215 vagina Anatomy 0.000 description 3
230000035899 viability Effects 0.000 description 3
229940118696 vibrio cholerae Drugs 0.000 description 3
FQTLCLSUCSAZDY-UHFFFAOYSA-N (+) E(S) nerolidol Natural products CC(C)=CCCC(C)=CCCC(C)(O)C=C FQTLCLSUCSAZDY-UHFFFAOYSA-N 0.000 description 2
CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 2
239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 2
CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 2
LBWCDROIOCXGGV-UHFFFAOYSA-N 2-(1,3,5-triazin-2-yl)ethanol Chemical compound OCCC1=NC=NC=N1 LBWCDROIOCXGGV-UHFFFAOYSA-N 0.000 description 2
BOXOEKMBBOGSLC-UHFFFAOYSA-M 2-(1-heptadecyl-4,5-dihydroimidazol-1-ium-1-yl)ethanol;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCC[N+]1(CCO)CCN=C1 BOXOEKMBBOGSLC-UHFFFAOYSA-M 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
108700042778 Antimicrobial Peptides Proteins 0.000 description 2
102000044503 Antimicrobial Peptides Human genes 0.000 description 2
241000203069 Archaea Species 0.000 description 2
241000193755 Bacillus cereus Species 0.000 description 2
206010060976 Bacillus infection Diseases 0.000 description 2
241000588832 Bordetella pertussis Species 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
238000011752 CBA/J (JAX™ mouse strain) Methods 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
240000001817 Cereus hexagonus Species 0.000 description 2
CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 2
241001115402 Ebolavirus Species 0.000 description 2
241000192125 Firmicutes Species 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102000010445 Lactoferrin Human genes 0.000 description 2
108010063045 Lactoferrin Proteins 0.000 description 2
241000222722 Leishmania <genus> Species 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
241000711408 Murine respirovirus Species 0.000 description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
FQTLCLSUCSAZDY-ATGUSINASA-N Nerolidol Chemical compound CC(C)=CCC\C(C)=C\CC[C@](C)(O)C=C FQTLCLSUCSAZDY-ATGUSINASA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
102000029797 Prion Human genes 0.000 description 2
108091000054 Prion Proteins 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
235000019484 Rapeseed oil Nutrition 0.000 description 2
235000019485 Safflower oil Nutrition 0.000 description 2
241000607142 Salmonella Species 0.000 description 2
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
241000607768 Shigella Species 0.000 description 2
235000019486 Sunflower oil Nutrition 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
241000710886 West Nile virus Species 0.000 description 2
125000003342 alkenyl group Chemical group 0.000 description 2
230000004075 alteration Effects 0.000 description 2
229940037003 alum Drugs 0.000 description 2
150000003868 ammonium compounds Chemical class 0.000 description 2
239000003945 anionic surfactant Substances 0.000 description 2
238000002832 anti-viral assay Methods 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
235000021302 avocado oil Nutrition 0.000 description 2
239000008163 avocado oil Substances 0.000 description 2
238000010009 beating Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
FXJNQQZSGLEFSR-UHFFFAOYSA-M benzyl-dimethyl-tetradecylazanium;chloride;hydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 FXJNQQZSGLEFSR-UHFFFAOYSA-M 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 description 2
239000003613 bile acid Substances 0.000 description 2
239000003124 biologic agent Substances 0.000 description 2
238000005415 bioluminescence Methods 0.000 description 2
230000029918 bioluminescence Effects 0.000 description 2
229910052797 bismuth Inorganic materials 0.000 description 2
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
239000004067 bulking agent Substances 0.000 description 2
239000000828 canola oil Substances 0.000 description 2
235000019519 canola oil Nutrition 0.000 description 2
239000000969 carrier Substances 0.000 description 2
108010079058 casein hydrolysate Proteins 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
229960000228 cetalkonium chloride Drugs 0.000 description 2
229960004830 cetylpyridinium Drugs 0.000 description 2
WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000001886 ciliary effect Effects 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000009615 deamination Effects 0.000 description 2
238000006481 deamination reaction Methods 0.000 description 2
230000008260 defense mechanism Effects 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
230000001627 detrimental effect Effects 0.000 description 2
239000010432 diamond Substances 0.000 description 2
102000038379 digestive enzymes Human genes 0.000 description 2
108091007734 digestive enzymes Proteins 0.000 description 2
125000006182 dimethyl benzyl group Chemical group 0.000 description 2
UINVIMVXKWJZJW-UHFFFAOYSA-M dimethyl-bis(8-methylnonyl)azanium;chloride Chemical compound [Cl-].CC(C)CCCCCCC[N+](C)(C)CCCCCCCC(C)C UINVIMVXKWJZJW-UHFFFAOYSA-M 0.000 description 2
LLDFSHBCVFHQIV-UHFFFAOYSA-M dimethyl-octadecyl-propylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCC LLDFSHBCVFHQIV-UHFFFAOYSA-M 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 2
238000004945 emulsification Methods 0.000 description 2
QJDRVNCBBIGOFZ-UHFFFAOYSA-M ethyl-dimethyl-(1-phenyltridecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC([N+](C)(C)CC)C1=CC=CC=C1 QJDRVNCBBIGOFZ-UHFFFAOYSA-M 0.000 description 2
229930002886 farnesol Natural products 0.000 description 2
229940043259 farnesol Drugs 0.000 description 2
206010016256 fatigue Diseases 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
238000011010 flushing procedure Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
235000013373 food additive Nutrition 0.000 description 2
239000002778 food additive Substances 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
230000002394 glycogenic effect Effects 0.000 description 2
210000004209 hair Anatomy 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
238000011597 hartley guinea pig Methods 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
150000004679 hydroxides Chemical class 0.000 description 2
UWNADWZGEHDQAB-UHFFFAOYSA-N i-Pr2C2H4i-Pr2 Natural products CC(C)CCC(C)C UWNADWZGEHDQAB-UHFFFAOYSA-N 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
230000016784 immunoglobulin production Effects 0.000 description 2
208000009449 inhalation anthrax Diseases 0.000 description 2
208000023372 inhalational anthrax Diseases 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
230000002361 ketogenic effect Effects 0.000 description 2
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
229940078795 lactoferrin Drugs 0.000 description 2
235000021242 lactoferrin Nutrition 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000004325 lysozyme Substances 0.000 description 2
229960000274 lysozyme Drugs 0.000 description 2
235000010335 lysozyme Nutrition 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
206010025482 malaise Diseases 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
210000004779 membrane envelope Anatomy 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
239000000693 micelle Substances 0.000 description 2
210000003097 mucus Anatomy 0.000 description 2
239000013642 negative control Substances 0.000 description 2
WASNIKZYIWZQIP-AWEZNQCLSA-N nerolidol Natural products CC(=CCCC(=CCC[C@@H](O)C=C)C)C WASNIKZYIWZQIP-AWEZNQCLSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
231100000344 non-irritating Toxicity 0.000 description 2
230000009972 noncorrosive effect Effects 0.000 description 2
229940087419 nonoxynol-9 Drugs 0.000 description 2
229920004918 nonoxynol-9 Polymers 0.000 description 2
231100000956 nontoxicity Toxicity 0.000 description 2
210000001331 nose Anatomy 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000003071 parasitic effect Effects 0.000 description 2
230000007918 pathogenicity Effects 0.000 description 2
230000035515 penetration Effects 0.000 description 2
230000008855 peristalsis Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000002510 pyrogen Substances 0.000 description 2
125000001453 quaternary ammonium group Chemical group 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
235000005713 safflower oil Nutrition 0.000 description 2
239000003813 safflower oil Substances 0.000 description 2
SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 2
239000002600 sunflower oil Substances 0.000 description 2
230000008093 supporting effect Effects 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000005891 transamination reaction Methods 0.000 description 2
RYVBINGWVJJDPU-UHFFFAOYSA-M tributyl(hexadecyl)phosphanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[P+](CCCC)(CCCC)CCCC RYVBINGWVJJDPU-UHFFFAOYSA-M 0.000 description 2
230000004102 tricarboxylic acid cycle Effects 0.000 description 2
230000005951 type IV hypersensitivity Effects 0.000 description 2
208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
230000003253 viricidal effect Effects 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
210000002268 wool Anatomy 0.000 description 2
LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
229940124718 AIDS vaccine Drugs 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000710929 Alphavirus Species 0.000 description 1
241000272478 Aquila Species 0.000 description 1
241000712891 Arenavirus Species 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241001225321 Aspergillus fumigatus Species 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
241000193752 Bacillus circulans Species 0.000 description 1
241000194107 Bacillus megaterium Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
229940124899 Biothrax Drugs 0.000 description 1
241000282817 Bovidae Species 0.000 description 1
241000589562 Brucella Species 0.000 description 1
241001136175 Burkholderia pseudomallei Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
101710082516 C-X-C chemokine receptor type 5 Proteins 0.000 description 1
241000282832 Camelidae Species 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
241001647378 Chlamydia psittaci Species 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
206010061043 Clostridial infection Diseases 0.000 description 1
241000193403 Clostridium Species 0.000 description 1
208000037384 Clostridium Infections Diseases 0.000 description 1
241000193155 Clostridium botulinum Species 0.000 description 1
241000193449 Clostridium tetani Species 0.000 description 1
241000759568 Corixa Species 0.000 description 1
241000606678 Coxiella burnetii Species 0.000 description 1
241000223936 Cryptosporidium parvum Species 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
241000282324 Felis Species 0.000 description 1
241000711950 Filoviridae Species 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
241000589601 Francisella Species 0.000 description 1
241000589602 Francisella tularensis Species 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
241000223218 Fusarium Species 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
229940033330 HIV vaccine Drugs 0.000 description 1
229940033332 HIV-1 vaccine Drugs 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241000712431 Influenza A virus Species 0.000 description 1
206010022086 Injection site pain Diseases 0.000 description 1
206010053425 Injection site swelling Diseases 0.000 description 1
108090000177 Interleukin-11 Proteins 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
241000712890 Junin mammarenavirus Species 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
229930182821 L-proline Natural products 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001115401 Marburgvirus Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
230000006051 NK cell activation Effects 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
241000526636 Nipah henipavirus Species 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000150452 Orthohantavirus Species 0.000 description 1
206010069586 Orthopox virus infection Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000002508 Peptide Elongation Factors Human genes 0.000 description 1
108010068204 Peptide Elongation Factors Proteins 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
241000425347 Phyla <beetle> Species 0.000 description 1
101000902411 Pinus strobus Pinosylvin synthase 1 Proteins 0.000 description 1
206010035667 Pneumonia anthrax Diseases 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
241000588770 Proteus mirabilis Species 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 1
108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 1
241001454523 Quillaja saponaria Species 0.000 description 1
240000000528 Ricinus communis Species 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
241000606701 Rickettsia Species 0.000 description 1
241000606697 Rickettsia prowazekii Species 0.000 description 1
241000315672 SARS coronavirus Species 0.000 description 1
101150067286 STS1 gene Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101100028967 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDR5 gene Proteins 0.000 description 1
241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000607764 Shigella dysenteriae Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
206010040914 Skin reaction Diseases 0.000 description 1
239000005708 Sodium hypochlorite Substances 0.000 description 1
241000589970 Spirochaetales Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
241000193985 Streptococcus agalactiae Species 0.000 description 1
201000005010 Streptococcus pneumonia Diseases 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
101150027289 Ubash3b gene Proteins 0.000 description 1
102100040338 Ubiquitin-associated and SH3 domain-containing protein B Human genes 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
241000607598 Vibrio Species 0.000 description 1
206010047400 Vibrio infections Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
241000607734 Yersinia <bacteria> Species 0.000 description 1
241000607447 Yersinia enterocolitica Species 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
208000025087 Yersinia pseudotuberculosis infectious disease Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
239000002535 acidifier Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
208000022338 anthrax infection Diseases 0.000 description 1
108010039069 anthrax toxin receptors Proteins 0.000 description 1
229960000754 anthrax vaccine adsorbed Drugs 0.000 description 1
229960005447 anthrax vaccines Drugs 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000001775 anti-pathogenic effect Effects 0.000 description 1
238000011203 antimicrobial therapy Methods 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
229940091771 aspergillus fumigatus Drugs 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
206010064097 avian influenza Diseases 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
229960001950 benzethonium chloride Drugs 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
IUHDTQIYNQQIBP-UHFFFAOYSA-M benzyl-ethyl-dimethylazanium;chloride Chemical compound [Cl-].CC[N+](C)(C)CC1=CC=CC=C1 IUHDTQIYNQQIBP-UHFFFAOYSA-M 0.000 description 1
YDCVSFADLJXKMY-UHFFFAOYSA-N benzylazanium;chloride;hydrate Chemical compound O.[Cl-].[NH3+]CC1=CC=CC=C1 YDCVSFADLJXKMY-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
229940115457 cetyldimethylethylammonium bromide Drugs 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
201000004836 cutaneous anthrax Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
230000010460 detection of virus Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
229940059082 douche Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000008029 eradication Effects 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
VUFOSBDICLTFMS-UHFFFAOYSA-M ethyl-hexadecyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)CC VUFOSBDICLTFMS-UHFFFAOYSA-M 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
230000004136 fatty acid synthesis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000021323 fish oil Nutrition 0.000 description 1
229940013317 fish oils Drugs 0.000 description 1
230000004907 flux Effects 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
229940118764 francisella tularensis Drugs 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
244000053095 fungal pathogen Species 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
230000034659 glycolysis Effects 0.000 description 1
230000006545 glycolytic metabolism Effects 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
231100001261 hazardous Toxicity 0.000 description 1
230000005802 health problem Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
244000038280 herbivores Species 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000008076 immune mechanism Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229960003971 influenza vaccine Drugs 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003999 initiator Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
230000007794 irritation Effects 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
239000010985 leather Substances 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
238000003670 luciferase enzyme activity assay Methods 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003550 marker Substances 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
239000010705 motor oil Substances 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
230000035772 mutation Effects 0.000 description 1
GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
244000309711 non-enveloped viruses Species 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
CBFCDTFDPHXCNY-UHFFFAOYSA-N octyldodecane Natural products CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
229940075930 picrate Drugs 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
239000010773 plant oil Substances 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
229920000056 polyoxyethylene ether Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000016412 positive regulation of cytokine production Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
229960002429 proline Drugs 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
230000005180 public health Effects 0.000 description 1
238000012797 qualification Methods 0.000 description 1
206010037844 rash Diseases 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
229940046939 rickettsia prowazekii Drugs 0.000 description 1
150000003902 salicylic acid esters Chemical class 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
235000017709 saponins Nutrition 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
229940007046 shigella dysenteriae Drugs 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
231100000430 skin reaction Toxicity 0.000 description 1
230000035483 skin reaction Effects 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
JFQQAVDBIXXGNH-UHFFFAOYSA-M sodium;dodecan-3-yl sulfate Chemical compound [Na+].CCCCCCCCCC(CC)OS([O-])(=O)=O JFQQAVDBIXXGNH-UHFFFAOYSA-M 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000007614 solvation Methods 0.000 description 1
230000004763 spore germination Effects 0.000 description 1
230000002623 sporogenic effect Effects 0.000 description 1
238000005507 spraying Methods 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000010408 sweeping Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000000954 titration curve Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
229960003500 triclosan Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
229940098232 yersinia enterocolitica Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
- C12N2710/24163—Methods of inactivation or attenuation by chemical treatment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Virology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Oncology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

CA002649457A 2006-04-13 2007-04-13 Vaccins a base d'une nanoemulsion Abandoned CA2649457A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA2912900A CA2912900A1 (fr)	2006-04-13	2007-04-13	Vaccins a base d'une nanoemulsion

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US79180006P	2006-04-13	2006-04-13
US79175806P	2006-04-13	2006-04-13
US79175906P	2006-04-13	2006-04-13
US60/791,759		2006-04-13
US60/791,800		2006-04-13
US60/791,758		2006-04-13
PCT/US2007/009208 WO2007120860A2 (fr)	2006-04-13	2007-04-13	Vaccins à base d'une nanoémulsion

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2912900A Division CA2912900A1 (fr)	2006-04-13	2007-04-13	Vaccins a base d'une nanoemulsion

Publications (1)

Publication Number	Publication Date
CA2649457A1 true CA2649457A1 (fr)	2007-10-25

Family

ID=38610224

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CA2912900A Abandoned CA2912900A1 (fr)	2006-04-13	2007-04-13	Vaccins a base d'une nanoemulsion
CA002649457A Abandoned CA2649457A1 (fr)	2006-04-13	2007-04-13	Vaccins a base d'une nanoemulsion

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CA2912900A Abandoned CA2912900A1 (fr)	2006-04-13	2007-04-13	Vaccins a base d'une nanoemulsion

Country Status (3)

Country	Link
EP (1)	EP2012771A4 (fr)
CA (2)	CA2912900A1 (fr)
WO (1)	WO2007120860A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9974844B2 (en) *	2008-11-17	2018-05-22	The Regents Of The University Of Michigan	Cancer vaccine compositions and methods of using the same
US8668911B2 (en) *	2009-05-14	2014-03-11	The Regents Of The University Of Michigan	Streptococcus vaccine compositions and methods of using the same
GB201801022D0 (en) *	2018-01-22	2018-03-07	Q Linea Ab	Single dye concentration determination
CN111303277A (zh) *	2020-02-19	2020-06-19	中国人民解放军军事科学院军事医学研究院	一种抗天花病毒免疫球蛋白F(ab′)2及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6015832A (en) *	1997-12-31	2000-01-18	The Regents Of The University Of Michigan	Methods of inactivating bacteria including bacterial spores
US7767216B2 (en) *	1999-04-28	2010-08-03	The Regents Of The University Of Michigan	Antimicrobial compositions and methods of use
EP2545937A1 (fr) *	2001-06-05	2013-01-16	The Regents Of The University Of Michigan	Vaccins en nanoémulsion
EP1633322A2 (fr) *	2003-06-04	2006-03-15	Nanobio Corporation	Compositions pour l'inactivation de micro-organismes pathogenes, procedes de fabrication de compositions, et leurs procedes d'utilisation

2007
- 2007-04-13 CA CA2912900A patent/CA2912900A1/fr not_active Abandoned
- 2007-04-13 CA CA002649457A patent/CA2649457A1/fr not_active Abandoned
- 2007-04-13 EP EP07755465A patent/EP2012771A4/fr not_active Ceased
- 2007-04-13 WO PCT/US2007/009208 patent/WO2007120860A2/fr active Application Filing

Also Published As

Publication number	Publication date
EP2012771A2 (fr)	2009-01-14
WO2007120860A2 (fr)	2007-10-25
CA2912900A1 (fr)	2007-10-25
EP2012771A4 (fr)	2010-01-27
WO2007120860A3 (fr)	2008-03-13

Legal Events

Date	Code	Title	Description
2008-10-09	EEER	Examination request
2016-01-12	FZDE	Discontinued	Effective date: 20151201

Publication	Publication Date	Title
US20120141526A1 (en)	2012-06-07	Nanoemulsion vaccines
US8877208B2 (en)	2014-11-04	Multivalent nanoemulsion vaccines
US20090291095A1 (en)	2009-11-26	Nanoemulsion adjuvants
US8668911B2 (en)	2014-03-11	Streptococcus vaccine compositions and methods of using the same
US9839685B2 (en)	2017-12-12	Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
JP6122083B2 (ja)	2017-04-26	ナノエマルションワクチン
US20140093537A1 (en)	2014-04-03	Immunogenic compositions comprising nanoemulsion and methods of administering the same
CA2649457A1 (fr)	2007-10-25	Vaccins a base d'une nanoemulsion
US10138279B2 (en)	2018-11-27	Compositions and methods for Bacillus anthracis vaccination
US20090068225A1 (en)	2009-03-12	Compositions and methods for orthopox virus vaccination
US20130273113A1 (en)	2013-10-17	Immunogenic apoptosis inducing compositions and methods of use thereof
AU2014201214B2 (en)	2016-06-09	Nanoemulsion vaccines
CN101466370A (zh)	2009-06-24	纳米乳剂疫苗
Haij et al.	2012	Cationic nanoglycolipidic particles as vector and adjuvant for the study of the immunogenicity of SIV Nef protein
Challenge	2007	Mucosal Immunization with a Novel